The BARD1 (ASX:BD1) share price eyes record highs after positive research results

The BARD1 Life Sciences Ltd (ASX: BD1) share price is eyeing a new record high today after positive results from its research study

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer

Let's take a closer look at the announcement and what this means for the BARD1 share price. 

What's driving the BARD1 share price higher? 

BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its proprietary Molecular NET technology. In particular, its lead EXO-NET product designed to capture and purify exosomes in a rapid, scalable and cost-effective manner. 

There are currently multiple EXO-NET evaluations underway. These evaluations are being conducted by various academic and industry partners. Notably, the partners include the University of Sydney, University of Queensland, Minomic International and VivaZome Therapeutics. 

On Tuesday, BARD1 announced positive results from a collaborative research study. The intention of the study was to evaluate its EXO-NET exosome capture technology and Minomic's anti-GPC-1 antibody. Primarily, this technology is used for the detection of pancreatic cancer. The study found that EXO-NET was highly effective at isolating exosomes from both pancreatic cancer and healthy control samples. While the anti-GPC-1 antibody appeared to bind specific pancreatic cancer exosomes for pancreatic cancer patients. 

BARD1 CEO, Dr Leearne Hinch was pleased with the results and commented on the next steps for EXO-NET: 

This is a very encouraging result that clearly demonstrates the commercial potential of our soon-to-be launched RUO EXO-NET™ product for capturing exosomes and the feasibility of using GPC-1+ exosomes for detection of pancreatic cancer. BARD1 and Minomic are extremely pleased by this outcome and will discuss how to advance the project towards development of an exosome-based GPC-1 test for early detection of pancreatic cancer to improve patient outcomes and survival for this important unmet need.

What's in store for 2021? 

BARD1 is making significant progress in the development and commercialisation of its diagnostic solutions. In particular, its BARD1, SubB2M, Molecular NETs, and hTRET platforms for healthcare professionals and patients.

BARD1 will continue to test the EXO-NET in collaboration with other academic and industry partners. The company believes the product is on track for commercial launch in 2021.

More recently, an Australian patent was granted for hTERT. The hTERT patent now has granted patents in Australia, China, Europe, Japan and the United States. Additionally, there are currently pending patents in Israel. Moreover, hTERT revenue is in its early days, with the product generating $148,140 for the half-year ended 31 December 2020. 

SubB2M is a unique cancer probe that is currently being used in in-house research programs for the detection and monitoring of prostate and pancreatic cancers and used in collaboration with Griffith University to develop SubB2M-based tests for the detection of ovarian and breast cancers. 

The company currently has a market capitalisation of approximately $230 million with $7.3 million cash at 31 December 2020. 

 

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »